This article requires a subscription to view the full text. You may purchase access to this article or login to access your subscription using the links below.
Abstract
Pemigatinib was effective in patients with cholangiocarcinomas with FGFR2 fusions or rearrangements.
- ©2020 American Association for Cancer Research.
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
May 2020
Volume 10, Issue 5
Volume 10, Issue 5
Pemigatinib Is Active in Some FGFR2-Altered Cholangiocarcinomas
Jump to section
Advertisement